Zai Lab Announces EMA Grants Orphan Drug Designation To Zocilurtatug Pelitecan, Delta-Like Ligand 3-Targeting Antibody-Drug Conjugate, For Treatment Of Pulmonary Neuroendocrine Carcinomas

Loading news article.

Zai Lab Announces EMA Grants Orphan Drug Designation To Zocilurtatug Pelitecan, Delta-Like Ligand 3-Targeting Antibody-Drug Conjugate, For Treatment Of Pulmonary Neuroendocrine Carcinomas | WAPE

Zai Lab Announces EMA Grants Orphan Drug Designation To Zocilurtatug Pelitecan, Delta-Like Ligand 3-Targeting Antibody-Drug Conjugate, For Treatment Of Pulmonary Neuroendocrine Carcinomas

Article summary

Related companies

Comments —